ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,00%
Bitcoin
66.983,11
-0,15%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) News

IFRX

InflaRx NV (IFRX)

InflaRx NV
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IFRX
DatumZeitQuelleÜberschriftSymbolFirma
08/05/202414h43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
08/05/202413h30GlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
30/04/202413h30GlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
24/04/202413h30GlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
21/03/202412h00GlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
19/03/202412h30GlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
22/02/202413h30GlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
25/01/202414h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
25/01/202413h30GlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
04/01/202422h16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
04/01/202413h00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
06/11/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
06/11/202313h30GlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
01/11/202313h04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
01/11/202312h30GlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
11/09/202314h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
11/09/202313h00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
30/08/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
30/08/202313h30GlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
10/08/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
10/08/202313h30GlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
12/07/202322h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
12/07/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
30/06/202322h06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
28/06/202314h31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
28/06/202314h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
28/06/202313h30GlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
21/06/202314h30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
21/06/202313h00GlobeNewswire Inc.InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
11/05/202313h30GlobeNewswire Inc.InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
 Showing the most relevant articles for your search:NASDAQ:IFRX

Kürzlich von Ihnen besucht

BIT
I06573
Banca Imi
BIT
X45597
Natixis Structured Issua...
BIT
IGD
Immobiliare Grande Distr...
AMEX
MBSD
FlexShares Disciplined D...
LSE
HEIC
Harmony Energy Income
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten